Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis (Diabetologia, 2023)

(untitled) - Yarmolinsky, J; Bouras, E; Constantinescu, A; Burrows, K; Bull, CJ; Vincent, EE; Martin, RM; Dimopoulou, O; Lewis, SJ; Moreno, V; Vujkovic, M; Chang, K-M; et al.